Cargando…

Procoagulant Microparticles in Dogs with Immune‐Mediated Hemolytic Anemia

BACKGROUND: Studies of some human prothrombotic diseases suggest that phosphatidylserine‐positive (PS+) and tissue factor‐positive (TF+) microparticles (MPs) might play a role in the pathogenesis of thrombosis or serve as biomarkers of thrombotic risk. HYPOTHESIS/OBJECTIVES: To determine if circulat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kidd, L., Geddings, J., Hisada, Y., Sueda, M., Concannon, T., Nichols, T., Merricks, E., Mackman, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895429/
https://www.ncbi.nlm.nih.gov/pubmed/25871966
http://dx.doi.org/10.1111/jvim.12583
_version_ 1782435846487539712
author Kidd, L.
Geddings, J.
Hisada, Y.
Sueda, M.
Concannon, T.
Nichols, T.
Merricks, E.
Mackman, N.
author_facet Kidd, L.
Geddings, J.
Hisada, Y.
Sueda, M.
Concannon, T.
Nichols, T.
Merricks, E.
Mackman, N.
author_sort Kidd, L.
collection PubMed
description BACKGROUND: Studies of some human prothrombotic diseases suggest that phosphatidylserine‐positive (PS+) and tissue factor‐positive (TF+) microparticles (MPs) might play a role in the pathogenesis of thrombosis or serve as biomarkers of thrombotic risk. HYPOTHESIS/OBJECTIVES: To determine if circulating levels of PS+MP and procoagulant activity (PCA) associated with PS+MPs and TF+ MPs are increased in dogs with IMHA. ANIMALS: Fifteen dogs with primary or secondary IMHA and 17 clinically healthy dogs. METHODS: Prospective case‐controlled observational study. Circulating PS+MPs were measured by flow cytometry. PCA associated with PS+MPs and TF+MPs was measured by thrombin and Factor Xa generating assays, respectively. RESULTS: Circulating numbers of PS+MPs were not significantly higher in dogs with IMHA [control median 251,000/μL (36,992–1,141,250/μL); IMHA median 361,990/μL (21,766–47,650,600/μL) P = .30]. However, PS+MP PCA [control median 2.2 (0.0–16.8) nM PS eq; IMHA median 8.596, (0–49.33 nM PS eq) P = .01] and TF+MP PCA [control median 0.0, (0.0–0.0 pg/mL); IMHA median 0.0; (0–22.34 pg/mL], P = .04) were increased. Intravascular hemolysis, which we showed might increase PS+ and TF+MP PCA, was evident in 3 of 5 dogs with PS+MP PCA and 2 of 4 dogs with TF+MP PCA higher than controls. Underlying disease in addition to IMHA was detected in 1 of 5 dogs with PS+PCA and 3 of 4 dogs with TF+MP PCA higher than controls. CONCLUSIONS AND CLINICAL IMPORTANCE: TF+ and PS+MP PCA is increased in some dogs with IMHA. Further studies that determine if measuring TF+ and PS+ MP PCA can help identify dogs at risk for thrombosis are warranted.
format Online
Article
Text
id pubmed-4895429
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-48954292016-06-22 Procoagulant Microparticles in Dogs with Immune‐Mediated Hemolytic Anemia Kidd, L. Geddings, J. Hisada, Y. Sueda, M. Concannon, T. Nichols, T. Merricks, E. Mackman, N. J Vet Intern Med Standard Articles BACKGROUND: Studies of some human prothrombotic diseases suggest that phosphatidylserine‐positive (PS+) and tissue factor‐positive (TF+) microparticles (MPs) might play a role in the pathogenesis of thrombosis or serve as biomarkers of thrombotic risk. HYPOTHESIS/OBJECTIVES: To determine if circulating levels of PS+MP and procoagulant activity (PCA) associated with PS+MPs and TF+ MPs are increased in dogs with IMHA. ANIMALS: Fifteen dogs with primary or secondary IMHA and 17 clinically healthy dogs. METHODS: Prospective case‐controlled observational study. Circulating PS+MPs were measured by flow cytometry. PCA associated with PS+MPs and TF+MPs was measured by thrombin and Factor Xa generating assays, respectively. RESULTS: Circulating numbers of PS+MPs were not significantly higher in dogs with IMHA [control median 251,000/μL (36,992–1,141,250/μL); IMHA median 361,990/μL (21,766–47,650,600/μL) P = .30]. However, PS+MP PCA [control median 2.2 (0.0–16.8) nM PS eq; IMHA median 8.596, (0–49.33 nM PS eq) P = .01] and TF+MP PCA [control median 0.0, (0.0–0.0 pg/mL); IMHA median 0.0; (0–22.34 pg/mL], P = .04) were increased. Intravascular hemolysis, which we showed might increase PS+ and TF+MP PCA, was evident in 3 of 5 dogs with PS+MP PCA and 2 of 4 dogs with TF+MP PCA higher than controls. Underlying disease in addition to IMHA was detected in 1 of 5 dogs with PS+PCA and 3 of 4 dogs with TF+MP PCA higher than controls. CONCLUSIONS AND CLINICAL IMPORTANCE: TF+ and PS+MP PCA is increased in some dogs with IMHA. Further studies that determine if measuring TF+ and PS+ MP PCA can help identify dogs at risk for thrombosis are warranted. John Wiley and Sons Inc. 2015-04-13 2015 /pmc/articles/PMC4895429/ /pubmed/25871966 http://dx.doi.org/10.1111/jvim.12583 Text en Copyright © 2015 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Standard Articles
Kidd, L.
Geddings, J.
Hisada, Y.
Sueda, M.
Concannon, T.
Nichols, T.
Merricks, E.
Mackman, N.
Procoagulant Microparticles in Dogs with Immune‐Mediated Hemolytic Anemia
title Procoagulant Microparticles in Dogs with Immune‐Mediated Hemolytic Anemia
title_full Procoagulant Microparticles in Dogs with Immune‐Mediated Hemolytic Anemia
title_fullStr Procoagulant Microparticles in Dogs with Immune‐Mediated Hemolytic Anemia
title_full_unstemmed Procoagulant Microparticles in Dogs with Immune‐Mediated Hemolytic Anemia
title_short Procoagulant Microparticles in Dogs with Immune‐Mediated Hemolytic Anemia
title_sort procoagulant microparticles in dogs with immune‐mediated hemolytic anemia
topic Standard Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895429/
https://www.ncbi.nlm.nih.gov/pubmed/25871966
http://dx.doi.org/10.1111/jvim.12583
work_keys_str_mv AT kiddl procoagulantmicroparticlesindogswithimmunemediatedhemolyticanemia
AT geddingsj procoagulantmicroparticlesindogswithimmunemediatedhemolyticanemia
AT hisaday procoagulantmicroparticlesindogswithimmunemediatedhemolyticanemia
AT suedam procoagulantmicroparticlesindogswithimmunemediatedhemolyticanemia
AT concannont procoagulantmicroparticlesindogswithimmunemediatedhemolyticanemia
AT nicholst procoagulantmicroparticlesindogswithimmunemediatedhemolyticanemia
AT merrickse procoagulantmicroparticlesindogswithimmunemediatedhemolyticanemia
AT mackmann procoagulantmicroparticlesindogswithimmunemediatedhemolyticanemia